NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer - Forbes
SAN DIEGO, Aug. 21 /PRNewswire/ — NovaRx Corporation announced today that the company initiated its pivotal Phase III clinical trial of Lucanix(R) (belagenpumatucel-L) in the treatment of advanced non-small cell lung cancer (NSCLC). The first
Passive smoking kills 7 people per day in Brazil - Xinhua News Agency
RIO DE JANEIRO, Aug. 22 (Xinhua) — The diseases caused by passive smoking kill seven people per day, or 2,655 people per year in Brazil, according to a study released on Friday. The study, released by the Rio de Janeiro State University and the
Lessons about life from my e-friend - Miami Herald
M y friend Leroy Sievers died on Aug. 15 at age 53. I considered him a friend, but the truth is I never actually met him. I read his ‘’My Cancer'’ blog on npr.com every day, and although I was never one of the many to post comments there, I read
Painter whose artworks imitated grand masters - Miami Herald
NEW YORK George Deem, a painter who admired master painters so much that he spent his own career repainting their works, albeit with clever alterations, died on Aug. 11 at home in Manhattan. He was 75. The cause was lung cancer, said Ronald Vance
Rolling With the Punches - Washington Post
After his brain tumor diagnosis in May, Ted Kennedy, with son Patrick and wife Vicki, leaves Massachusetts General Hospital in Boston. (By Darren Mccollester — Getty Images) The cancer-stricken Massachusetts senator, with wife Vicki. “My guy’s a
Freedom To Choose Welcomes New Research On Lung Cancer - PR Inside
Experts at the pro-choice group Freedom2Choose have acknowledged the conclusions of this report, presented at the American Chemical Society only this week, noting that it seeks to explain the disparities with the claims of tobacco control. It is also
Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial - Forbes
ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ — Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination